Multimorbidity Mechanism and Therapeutics Research Collaborative

As people live to a greater age there is an increased risk of suffering more than one health condition at a time. Known as multimorbidity this has a serious effect on the daily lives of patients, their families and their carers. The project will examine the sequence and patterns of multimorbidity and the evidence obtained will aid both the prediction and treatment of patients with multiple health conditions. We will also seek to address the problem of coordinating treatments so that treatment for one condition does not cause difficulties in the treatment of another condition suffered by the same patient. The frequency of this "competition" between health conditions will be established and solutions identified. In doing this we hope to identify medicines that are able to treat more than one condition and investigate the potential of new uses for existing safe medicines.
Our research will utilise anonymous patient data recorded by the NHS as well as the findings from existing genetic studies and clinical trials. We will look across the different types of evidence to check consistency to ensure our recommendations are sound. Where uncertainties remain we will recommend new clinical trials or genetic studies. In this way we hope to improve the outlook for patients, regardless of their particular combination of health conditions, by maximising the benefits from effective treatments.
Two patient participants are co-applicants on this project. A Patient and Public Advisory Group will be established which will also assist in ensuring that the findings from the project are widely disseminated. During the course of our work we will liaise with organisations such as the Coalition for Collaborative Care with a view to the establishment of a national Multimorbidity Special Interest Group.

Our research will uncover mechanisms underlying multimorbidity by triangulating relationships between medicines, drug targets and disease outcomes from electronic health records (EHRs), genetic association studies and trials. The findings will maximise treatment benefits by guiding drug indication expansion and re-purposing; reduce harm by optimising prescribing when diseases co-exist; and yield new tools for prediction and prevention of multi-morbidity.